Welcome to our dedicated page for COGNITION THERAPEUTICS news (Ticker: CGTX), a resource for investors and traders seeking the latest updates and insights on COGNITION THERAPEUTICS stock.
Cognition Therapeutics, Inc. (NASDAQ: CGTX) is a clinical-stage biopharmaceutical company developing small molecule therapeutics for age-related degenerative disorders of the central nervous system. Its news flow centers on the clinical and regulatory progress of its lead candidate, zervimesine (CT1812), an investigational oral pill in development for Alzheimer’s disease, dementia with Lewy bodies (DLB) and related conditions.
News updates from Cognition Therapeutics frequently cover milestones in its Phase 2 clinical programs. These include results and analyses from the SHINE study in mild-to-moderate Alzheimer’s disease, the SHIMMER study in mild-to-moderate DLB, and the START study in early Alzheimer’s disease. Articles describe safety and tolerability outcomes, changes in cognition and function measured by validated scales, and exploratory findings in behavioral, movement and neuropsychiatric domains.
Investors following CGTX news also see announcements about expanded access programs for zervimesine in DLB, collaborations with organizations such as the Alzheimer’s Clinical Trials Consortium, and substantial grant support from the National Institute on Aging of the National Institutes of Health. Regulatory and scientific updates, such as end-of-Phase 2 discussions with the U.S. Food and Drug Administration, Type C meeting plans, and presentations at major Alzheimer’s disease conferences, are regular features of the company’s news cycle.
In addition, Cognition Therapeutics issues press releases on financing transactions, including registered direct offerings of common stock and at-the-market equity programs, which provide context on how it funds ongoing and planned studies. For readers tracking CGTX, this news page consolidates clinical, regulatory, scientific and capital markets developments related to zervimesine and the company’s broader neurodegenerative disease pipeline.
Cognition Therapeutics announced the publication of a review article in the International Journal of Molecular Sciences discussing the mechanistic rationale for sigma-2 receptor modulation in age-related degenerative diseases including Alzheimer's disease and dementia with Lewy bodies. The article highlights the role of the sigma-2 receptor in neuronal function and its potential as a therapeutic target. Cognition's lead compound, CT1812, aims to advance to Phase 2 clinical trials. The study focuses on restoring synaptic health by targeting cellular processes impaired by neurodegenerative diseases. Cognition’s strategy underscores the unique mechanism of CT1812 in addressing significant unmet medical needs in neurodegeneration.
On March 28, 2023, Cognition Therapeutics (NASDAQ: CGTX) disclosed findings from a meta-analysis involving 24 participants in the Phase 2 SHINE-A study and data from the Phase 1b SPARC study. The results indicate that treatment with CT1812 yields statistically significant effects on key Alzheimer's disease markers, notably improving synapse health and reducing neuroinflammation. Notable changes in cerebrospinal fluid levels of clusterin and prion protein were observed, underscoring CT1812's potential in altering disease processes. These results were presented at the AD/PD™ 2023 conference, enhancing understanding of CT1812's therapeutic effects.
Cognition Therapeutics (Nasdaq: CGTX) has released its fourth video podcast discussing dementia with Lewy bodies (DLB), featuring insights from four neuroscience experts. The podcast highlights the overlap between DLB, Alzheimer’s, and Parkinson’s diseases, including symptoms, clinical features, and the importance of accurate diagnosis. Currently, there are no approved disease-modifying treatments for DLB, which affects about 1.4 million Americans. The company is conducting the Phase 2 SHIMMER study for its lead candidate, CT1812, with a $30M grant from the NIH’s National Institute on Aging to evaluate treatment effects on DLB.
Cognition Therapeutics, Inc. (Nasdaq: CGTX) has announced significant progress in its clinical development, including the completion of enrollment in the Phase 2 SEQUEL study for mild-to-moderate Alzheimer's disease. The company received FDA clearance for the Phase 2 START study and the IND for a Phase 2 study targeting geographic atrophy due to dry AMD. Financially, the company secured an equity commitment of up to $35 million and raised $6 million through a public offering, with cash reserves expected to fund operations into the second half of 2024. However, Cognition reported a net loss of $21.4 million for 2022, reflecting increased R&D and G&A expenses.
Cognition Therapeutics, Inc. (NASDAQ: CGTX) will present results from a proteomic biomarker meta-analysis of cerebrospinal fluid samples from participants in their Phase 2 SHINE and Phase 1b SPARC studies, focusing on mild-to-moderate Alzheimer's disease. The analysis identified biomarkers of CT1812 activity, which inform the understanding of Alzheimer's progression. A poster presentation is scheduled at the AD/PD™ 2023 conference in Gothenburg, Sweden, from March 28 to April 1, 2023. Additionally, CEO Lisa Ricciardi will participate in a panel on innovative approaches to Alzheimer's research on March 29, emphasizing the importance of rigorous clinical trials.
Cognition Therapeutics, Inc. (Nasdaq: CGTX) announced a conference call set for March 23, 2023, at 8:00 a.m. ET to review its financial results for the fourth quarter and full year ended December 31, 2022. The results will be released before the market opens on the same day. Participants can access the call via a toll-free dial-in or through a live audio webcast on the company's Investor Relations page. Cognition is focused on developing treatments for neurodegenerative disorders, with its lead candidate CT1812 targeting Alzheimer's and related conditions.
Cognition Therapeutics announced that the FDA has cleared its IND application for CT1812, aimed at treating geographic atrophy (GA) secondary to dry age-related macular degeneration (dry AMD). The Phase 2 MAGNIFY trial is set to commence in 2023, enrolling about 246 participants diagnosed with dry AMD and measurable GA. CT1812 is designed to protect retinal pigment epithelium (RPE) cells from damage, potentially slowing vision loss in patients. This trial expands the company's pipeline, highlighting its ability to address challenging diseases.
Cognition Therapeutics, Inc. (Nasdaq: CGTX) announced that its president and CEO, Lisa Ricciardi, will present at the Oppenheimer & Co Healthcare Conference occurring virtually from March 13-15, 2023. Ricciardi's presentation is scheduled for March 15, 2023, at 10:00 a.m. ET, where she will discuss the company's pipeline progress, recent achievements, and future milestones. Interested investors can access the live webcast and subsequent archived replay via the company’s investor site. Cognition Therapeutics focuses on developing therapeutics targeting age-related degenerative disorders, particularly through its lead candidate CT1812 aimed at treating Alzheimer’s disease and other related conditions.
Cognition Therapeutics (CGTX) has received FDA clearance to commence its 540-patient Phase 2 START study of CT1812 for early Alzheimer's disease. This innovative oral small molecule aims to block toxic beta amyloid effects on neurons. The study will be conducted at 50-60 North American sites and is backed by an $81 million NIH grant over five years. Initial results of CT1812 have been encouraging, and further investigation is expected to enhance treatment options for Alzheimer's. The trial will evaluate CT1812's efficacy and safety over 18 months against placebo, utilizing established cognitive assessment tools.
Cognition Therapeutics, Inc. (Nasdaq: CGTX) has launched its third podcast episode focused on Lewy body dementia, featuring caregivers who share their experiences and insights. The podcast, moderated by CEO Lisa Ricciardi, highlights key symptoms, preparation for doctor visits, and the challenges faced by caregivers. Lewy body dementias, affecting approximately 1.4 million Americans, include Parkinson’s disease dementia and dementia with Lewy bodies, sharing symptoms such as cognitive impairment and visual hallucinations. The company is conducting a Phase 2 SHIMMER trial for its candidate CT1812, with support from a $30M NIH grant.
FAQ
What is the current stock price of COGNITION THERAPEUTICS (CGTX)?
What is the market cap of COGNITION THERAPEUTICS (CGTX)?
